We report a rare case of KIT-negative extra-gastrointestinal stromal tumor, in a 40-year-old woman. Contrast-enhanced computed tomography and magnetic resonance imaging revealed a >15-cm mass of multiple cystic lesions in the greater omentum. Histopathological findings after surgery showed a sheet-like growth of stellate tumor cells from epithelial cells, cystic degeneration, and mucus-like stroma. Immunohistochemistry was positive for discovered on GIST-1 (DOG1) but negative for CD117 (c-kit).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237296 | PMC |
| http://dx.doi.org/10.1016/j.radcr.2021.05.061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gastrointestinal stromal tumors or GISTs are the most common mesenchymal tumors of the gastrointestinal tract; only a few cases have been reported at other sites. The prognosis of GISTs depends on their size and mitotic rate. Surgical removal is the treatment of choice although imatinib shows clinical benefits.
View Article and Find Full Text PDFIsolated liver gastrointestinal stromal tumor: A case report.
J Clin Ultrasound
October 2024
Department of Ultrasound in Medicine, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Article Synopsis
- A case study detailed a 38-year-old man with multiple cystic-solid liver lesions, ultimately diagnosed as a liver GIST after a CT-guided biopsy, but distinguishing between PLGIST and LMGIST was complicated due to missing medical history.
- The study emphasizes the importance of understanding this rare liver tumor type for better diagnosis and staging, especially as the lesions increased in size during a two-year follow-up without any other lesions found outside the liver.
Rare Double Primary Malignancies: A Pancreatic Gastrointestinal Stromal Tumor Mimicking as a Metastatic Lesion of Myoepithelial Carcinoma of Parotid Gland.
Case Rep Med
December 2023
Staff of Digestive Division of General Surgery Department, Faculty of Medicine, Universitas Indonesia, General Surgery Department, Cipto Mangunkusumo Hospital, Diponegoro Street #71, Senen, Central Jakarta, Indonesia.
Pancreatic gastrointestinal stromal tumors (PGISTs) are exceptionally rare, accounting for <5% of extra-gastrointestinal stromal tumors (EGISTs) and <1% of malignant pancreatic neoplasms. We present a unique case of concurrent double primary malignancies in a 46-year-old female with a history of recurrent myoepithelial carcinoma of the parotid gland, managed through surgical resection and adjuvant therapy. She presented with an enlarging abdominal mass, initially suggestive of pancreatic metastasis.
View Article and Find Full Text PDFTumor Microenvironment Biomarkers Correlated with Proliferative Activity and Immune Response in Extragastrointestinal Stromal Tumors: Exploring Variations in Different Age Groups.
Maedica (Bucur)
June 2024
Department of Pathology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Introduction: Extra-gastrointestinal stromal tumors (EGISTs) are non-gastrointestinal sarcomas originating from Cajal-like cells. Recent studies show the tumor microenvironment is crucial and highlight the importance of intra-tumoral leukocyte populations in malignancies, which are greatly impacting treatment strategies in EGISTs.
Aim And Objectives: This study aims to characterize intra-tumoral leukocyte populations in EGISTs, correlating proliferative index (ki67) with leukocyte density and examining age-related effects on proliferative activity and immune response.
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report.
Front Oncol
August 2024
Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia. ASST Spedali Civili, Brescia, Italy.
Article Synopsis
- Regorafenib is an oral medication used to treat certain types of tumors, including metastatic gastrointestinal stromal tumors (GIST), and is typically considered after other treatments fail.
- In a case involving a 58-year-old woman, regorafenib was linked to increased levels of red blood cells and hemoglobin, which is not a commonly reported side effect of this drug.
- The case suggests that the observed increase in red blood cell counts may not be related to dosage but could indicate the drug's effectiveness, highlighting the need for monitoring blood levels in patients on regorafenib.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!